US-based biotechnology firm Tetragenetics will enter into collaboration with AstraZeneca’s global biologics research and development arm MedImmune, on multi-target ion channel drug discovery program.
{iframe}http://www.pharmaceutical-business-review.com/news/tetragenetics-to-partner-with-medimmune-on-antibody-drug-discovery-research-080115-4484552{/iframe}